Biomarker Basics

As this blog focuses on reviewing scientific papers describing biomarker discovery, validation and clinical use, we felt that it was time to pause and review some biomarker basics.

What is a biomarker? A biomarker can be objectively measured to assess a biologic process, a disease process, or a response to a treatment or lifestyle change.1 Almost […]

Plasma 1-Deoxysphingolipid Predicts Type 2 Diabetes in At-Risk Population

A research team led by Alaa Othman1 explored the “lipidome” to identify novel risk factors or biomarkers that predict the incidence of type 2 diabetes. The researchers measured sphingoid base profiles in a prospective cohort of 339 individuals who had already experienced a coronary event. The team determined whether this data could help predict which […]

By |October 14th, 2015|Diabetes|0 Comments

Anti-inflammatory Drugs Might Someday Treat Obesity

Obesity leads to chronic, low-grade local inflammation in the liver and adipose tissue. This local inflammation eventually results in insulin resistance and the development of type 2 diabetes. American researcher Jonathan Mowers and his team1 explored the complex molecular pathways linking obesity, inflammation and diabetes. Their investigation identified two potential therapeutic targets.

Previously, these researchers observed […]

By |October 7th, 2015|Diabetes, Obesity|0 Comments

SGLT2 Inhibitor Phlorizin and Diabetic Heart Disease

The big news from the 2015 European Association for the Study of Diabetes (EASD) meeting in Stockholm was that diabetic patients treated with a sodium-glucose co-transporter 2 (SGLT2) inhibitor experienced better cardiovascular outcomes than those treated with placebo and standard of care. The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG […]

By |September 28th, 2015|Diabetes|0 Comments

Measuring IGF1 – Future Direction for MS in the Clinical Lab

The peptide hormone insulin-like growth factor 1 (IGF1) is involved in a wide spectrum of biological processes.1 It is present in nanomolar amounts in blood. IGF-binding proteins modulate IGF1. Because the hormone is a marker for multiple disorders including osteoporosis, diabetes, obesity, neuromuscular disorders, growth hormone resistance and insulin resistance, accurate measurement of IGF1 levels […]

By |September 21st, 2015|Diabetes, Obesity|0 Comments

Metabolic Changes Precede Clinical Symptoms in Type 2 Diabetes

Type 2 diabetes is primarily defined by elevated blood glucose, but other disease characteristics include central obesity and a lack of physical activity. The earliest molecular changes leading to type 2 diabetes are not well defined but are thought to include blood vessel dysfunction in addition to a rise in blood glucose. A research team […]

By |September 9th, 2015|Diabetes|0 Comments

New Mass Spectrometry Immunoassay Detects Insulin and Analogues

Insulin is a peptide hormone produced by the beta cells of the pancreas. It is secreted into the plasma to promote efficient glucose utilization and to maintain glucose homeostasis. Measuring the levels of insulin can be challenging as it is present in very small quantities (sub ng/ml) in a complex biological matrix, so must be […]

By |July 3rd, 2015|Diabetes|0 Comments

Uncovering the Complex Origins of Diabetes

According to the 2014 National Diabetes Statistics Report published by the US Center for Disease Control and Prevention1, an estimated 29.1 million Americans, or 9.3% of the US population have diabetes. This number will continue increasing in the next few decades. Once simplistically viewed as a disease of impaired glucose metabolism, diabetes is now recognized […]

By |July 3rd, 2015|Diabetes|0 Comments